Neuroscience Antibodies & Assays Market Report 2026

Neuroscience Antibodies & Assays Market Overview

• Neuroscience Antibodies & Assays market size has reached to $5.03 billion in 2025 • Expected to grow to $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 14.3% • Growth Driver: Surge In Neurological Illnesses Spurs Remarkable Growth In The Neuroscience Antibodies & Assays Market • Market Trend: Next-Generation Immunoassays Enable Non-Invasive Brain Health Monitoring • North America was the largest region in 2025.

What Is Covered Under Neuroscience Antibodies & Assays Market?

The neuroscience antibodies & assays are used to study the development, systems, structure and function, disorders, and degeneration of the nervous system. Neuroscience is the study of the nervous system, its working, and diseases related to the nervous system. Antibodies and assays is a medical test that is based on principles of interaction between antigenic epitopes and antibodies, and this test is useful in neuroscience and the study of neurological disorders. The main types of neuroscience antibodies & assays market products are consumables, and instruments. Consumables are used in many neurological studies and research experiments. Consumable includes assay kits, reagents, and antibodies that enable quantitative and real-time live-cell analysis. The technologies used are molecular diagnostics, clinical chemistry, immunoassays or immunochemistry, and other technologies. The various applications are in vitro diagnostics, research, and drug discovery. The various end users are hospitals and diagnostics centers, academic and research institutes, pharmaceutical and biotechnology companies.

What Is The Neuroscience Antibodies & Assays Market Growth Forecast?

The neuroscience antibodies & assays market size is expected to see rapid growth in the next few years. It will grow to $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing investments in neurodegenerative disease research, rising demand for personalized neurology diagnostics, expansion of drug discovery programs, growing adoption of automated assay platforms, increasing focus on early disease detection. Major trends in the forecast period include increasing adoption of high-specificity antibody reagents, rising use of multiplex assay platforms, growing integration of automation in neuro research labs, expansion of biomarker-based neurological studies, enhanced focus on reproducibility and sensitivity.

Global Neuroscience Antibodies & Assays Market Segmentation

1) By Product: Consumables, Instruments 2) By Technology: Molecular Diagnostics, Immunoassays Or Immunochemistry, Other Technologies 3) By Application: In Vitro Diagnostics, Research, Drug Discovery 4) By End User: Hospitals And Diagnostics Centers, Academic And Research Institutes, Pharmaceutical And Biotechnology Companies Subsegments: 1) By Consumables: Antibodies, Assay Kits 2) By Instruments: Spectrophotometers, Microplate Readers, Flow Cytometers, Western Blotting Systems, Imaging Systems, Automated Workstations

What Is The Driver Of The Neuroscience Antibodies & Assays Market?

The increase in incidents of neurological illnesses is expected to propel the growth of the neuroscience antibodies and assays market going forward. Neurological illnesses are disorders affecting the brain, spinal cord, and nerves that result in impaired cognitive, motor, or sensory functions. The rising incidents of neurological illnesses are largely driven by population aging, as the growing proportion of older adults in developed countries increases the prevalence of age-related neurological conditions such as Alzheimer's disease and Parkinson's disease. Increasing neurological illness incidents support demand for specialized antibodies and assays because researchers and clinicians require these diagnostic and research tools to detect, study, and monitor disease-specific biomarkers and protein abnormalities in neurological conditions. For instance, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, in 2023, approximately 6.7 million Americans aged 65 and older are living with Alzheimer's dementia, and this number is projected to rise to 13.8 million by 2060. Therefore, the increase in incidents of neurological illnesses is driving the growth of the neuroscience antibodies and assays market.

Key Players In The Global Neuroscience Antibodies & Assays Market

Major companies operating in the neuroscience antibodies & assays market are Abcam plc, BioLegend Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Merck KGaA, Rockland Immunochemicals Inc., GenScript Biotech Corporation, Santa Cruz Biotechnology Inc., Wak-Chemie Medical GmbH, Epitope Diagnostics Inc., Agilent Technologies, Bio-Techne Corporation, Creative Diagnostics, Enzo Life Sciences Inc., Jackson ImmunoResearch Laboratories Inc., Novus Biologicals LLC, OriGene Technologies Inc., Proteintech Group Inc., R&D Systems Inc., RayBiotech Inc., StressMarq Biosciences Inc., Synaptic Systems GmbH, Tocris Bioscience, Alomone Labs Ltd., AnaSpec Inc., Antibodies.com, Antibody Solutions, Arbor Assays, Uscn Life Science Inc., Zymo Research Corp., AAT Bioquest Inc., Abbexa Ltd., ACROBiosystems Inc., Active Motif Inc., AdipoGen Life Sciences, Advanced Targeting Systems Inc., AgriSera AB

Global Neuroscience Antibodies & Assays Market Trends and Insights

Major companies operating in the neuroscience antibodies and assays market are focusing on developing innovative products, such as bispecific in vivo–ready antibodies, to simultaneously target multiple neurological pathways for more precise and effective research outcomes. Bispecific in vivo–ready antibodies are engineered to bind two different targets simultaneously and are formulated for use in live animal models, helping researchers modulate multiple neurological pathways at once for more precise and physiologically relevant neuroscience studies. For instance, in October 2025, Bio X Cell LLC, a US–based biotechnology company, launched an expanded catalog of bispecific and ADC (antibody-drug conjugate) antibodies as part of its refreshed brand identity, targeting advanced preclinical neuroscience and translational research applications. These bispecific antibodies are engineered to bind two distinct antigens simultaneously, allowing researchers to modulate multiple signaling pathways or cell populations in the brain within a single study, unlike traditional monoclonal antibodies that target only one molecule. They are produced with high purity (≥ 95%) and ultra-low endotoxin levels (≤ 0.5 EU/mg), making them suitable for sensitive in vivo experiments, organoid models, and organ-on-chip systems. The ADCs combine a functional antibody with a cytotoxic payload to selectively target specific neuronal or glial populations, offering precise modulation and experimental flexibility.

What Are Latest Mergers And Acquisitions In The Neuroscience Antibodies & Assays Market?

In December 2023, Danaher Corporation, a US-based life sciences & diagnostics company, acquired Abcam plc for an undisclosed amount. With this acquisition, Danaher aimed to expand its life science reagents and consumables platform, enhance its protein tool capabilities for research and diagnostics, accelerate growth in the life sciences ecosystem, and bolster its global reach in supplying integrated solutions to researchers and clinicians. Abcam plc is a UK-based biotechnology company that specializes in providing antibodies, reagents, assays and related life science research tools.

Regional Outlook

North America was the largest region in the neuroscience antibodies & assays market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Neuroscience Antibodies & Assays Market?

The neuroscience antibodies & assays market consists of sales of antibodies and assay kits and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.